GlassScriptPhysician profile
Holly B Miller
NPI 1053492686
$1,519.52
in general payments reported to CMS, 2019-2025
16 companies · $772 in 2025
The $772 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.35 · 2024: $650 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $272.35 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $210.40 | 2024-2025 | |
| Lilly USA, LLC | $205.05 | 2024-2025 | Kisunla, Emgality |
| Ucb, INC. | $191.60 | 2024-2025 | Briviact |
| Novartis Pharmaceuticals Corporation | $149.41 | 2024-2025 | |
| Abbvie INC. | $147.07 | 2025 | |
| Neurocrine Biosciences, INC. | $112.21 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $50.28 | 2024-2025 | Vyepti |
| United Therapeutics Corporation | $36.26 | 2021 | |
| Sk Life Science, INC. | $23.57 | 2025 | |
| Merz Pharmaceuticals, LLC | $23.33 | 2025 | Xeomin |
| Boston Scientific Corporation | $22.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.48 | 2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $20.03 | 2021 | |
| Medtronic, INC. | $18.56 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $16.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.